Skip to main content
EGF Theramed Health Corp. logo

EGF Theramed Health Corp. — Investor Relations & Filings

Ticker · TMED ISIN · CA30050R1064 LEI · 529900DF1TUGJAJ80V18 CSE Professional, scientific and technical activities
Filings indexed 395 across all filing types
Latest filing 2026-03-04 Regulatory Filings
Country CA Canada
Listing CSE TMED

About EGF Theramed Health Corp.

https://www.egftheramedhealth.com/

EGF Theramed Health Corp. is an early-stage development company specializing in biotechnological products and personalized medical care solutions. The company's primary focus is the development of psychedelic drugs intended for the treatment of various mental health problems. Additionally, EGF Theramed develops technologies, diagnostic tools, and biomedical online services aimed at monitoring and treating common health issues, positioning its offerings within the consumer technology and pharmaceutical development sectors.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-03-04 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-02-24 English
Interim MD&A - English.pdf
Regulatory Filings
2026-02-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2026-02-24 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Consolidated Financial Statements' for the three months ended September 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss, Statement of Changes in Shareholders' Deficiency, Statement of Cash Flows) and detailed notes to the financial statements. It is a formal quarterly financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2025-11-27 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is explicitly titled 'MANAGEMENT'S DISCUSSION AND ANALYSIS' (MD&A) for the three months ended September 30, 2025. It references 'FORM 51-102F1', which is the standard Canadian regulatory form for quarterly management discussion and analysis. It provides a detailed narrative explanation of financial results, business trends, and operational outlook, which aligns perfectly with the definition of an MDA filing.
2025-11-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.